Breaking Finance News

Roche Holdings (PK:RHHBY) has been downgraded from Buy to Hold in a report by Deutsche Bank today.

Deutsche Bank has downgraded Roche Holdings (PK:RHHBY) from Buy to Hold in a report released on 7/7/2017.

Only yesterday Roche Holdings (PK:RHHBY) traded 0.06% higher at $31.39. RHHBY’s 50-day average is $31.83 and its two hundred day average is $31.96. With the last stock price down -1.50% relative to the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 432,547 shares of RHHBY traded hands, down from an average trading volume of 1,669,710

Recent Performance Chart

Roche Holdings (PK:RHHBY)

Roche Holdings has 52 week low of $25.25 and a 52 week high of $36.82 with a price-earnings ratio of 21.59 and has a total market value of $0.

Brief Synopsis About Roche Holdings (PK:RHHBY)

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.